The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?
Abstract
Diabetes mellitus and obesity represent a growing global health burden with high morbidity and mortality. In the last several years, novel incretin-based therapies have been developed, and their use has risen dramatically. Beyond their proven metabolic, glycemic, cardiovascular, renal, and many other benefits, there are some observational data linking anemia development with their use. From the era of gliptins to retatrutide, in this review we tried to explore whether erythroid suppression is the hidden paradigm of advanced incretin-based therapies. Potential pathophysiological explanations include micronutrient vulnerabilities due to reduced food intake, lower dietary diversity, gastrointestinal intolerance, delayed gastric emptying, and weight loss. The most important concerns involve deficiencies in iron, vitamin B12, vitamin B2, vitamin D, calcium, magnesium, and zinc, along with others such as thiamine, folate, vitamin A, and potassium. The available evidence indicates a complex and heterogeneous relationship between incretin-based therapies and hematological parameters, with findings differing across therapies, study populations, and outcomes. Although observational studies suggest possible associations with anemia, iron deficiency, and nutritional deficiencies in selected populations, current evidence is insufficient to establish a direct causal relationship or a class-wide adverse effect. Further large-scale studies are needed, as well as increased clinician…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.